Aboubakr H. Abdelmonsef | Drug Design | Best Researcher Award

Assoc. Prof. Dr. Aboubakr H. Abdelmonsef | Drug Design | Best Researcher Award

Associate Professor, at South Valley University- Faculty of Science, Egypt. 

Dr. Aboubakr Haredi Abdelmonsef is an Associate Professor specializing in Organic Chemistry, Bioinformatics, and Drug Design at South Valley University, Egypt. With a strong foundation in organic chemistry and computational biology, he has established himself as a prominent figure in medicinal chemistry. Dr. Abdelmonsef’s research focuses on synthesizing biologically active molecules, analyzing their structural properties, and developing computational models to facilitate drug discovery. Over the years, he has contributed to various research projects, published extensively in peer-reviewed journals, and presented at numerous international conferences. His dedication to advancing science is reflected in his impressive publication record and the impact of his work, as highlighted by his h-index of 17 on Scopus. Dr. Abdelmonsef is known for his interdisciplinary approach, integrating organic synthesis and bioinformatics to address pressing health challenges.

Profile

Scopus

Google Scholar

ORCID

Education 🎓

Dr. Abdelmonsef received his Ph.D. in Chemistry from Osmania University, India, where he specialized in organic chemistry and computational studies for drug discovery. He also attended Jacobs University Bremen, Germany, as a visiting Ph.D. student, where he enhanced his expertise in computational chemistry. His doctoral work, which combined experimental synthesis with computational approaches, laid the foundation for his later contributions in bioinformatics and drug design. Dr. Abdelmonsef began his academic journey with a solid background in chemistry, progressively expanding his expertise into bioinformatics. This diverse educational background has enabled him to bridge gaps between organic synthesis and computational biology, making him a valuable asset in interdisciplinary research within his field.

Experience đź’Ľ

Dr. Abdelmonsef is an Associate Professor at South Valley University’s Chemistry Department, where he has taught and conducted research since 2006. His academic journey includes roles as an Assistant Professor, Assistant Lecturer, and Teaching Assistant. He also gained international experience as a visiting Ph.D. student at Jacobs University in Germany, enhancing his skills in computational modeling. His research career began with roles focusing on organic synthesis, gradually evolving to include bioinformatics and computational drug design. Throughout his career, he has supervised students, led workshops, and published extensively, making significant contributions to medicinal chemistry and bioinformatics. His multifaceted experience reflects his dedication to both academia and practical applications in chemical research.

Research Interests 🔬

Dr. Abdelmonsef’s research interests lie at the intersection of organic chemistry, bioinformatics, and drug design. He is particularly focused on developing and synthesizing novel bioactive molecules and using computational tools to understand their interactions with biological targets. His work includes molecular docking, QSAR studies, and in silico screening, aiming to accelerate drug discovery and address challenges in antimicrobial and anticancer therapy. Additionally, he explores the structural properties of heterocyclic compounds and their potential as therapeutic agents. Dr. Abdelmonsef’s interdisciplinary approach combines traditional synthesis with advanced computational techniques, allowing him to contribute valuable insights into bioactive molecule design and the potential development of new pharmaceuticals.

Awards 🏆

Dr. Abdelmonsef has received several accolades for his contributions to chemistry, including recognition for his research on bioactive molecules and computational drug design. His work has garnered both national and international attention, emphasizing his commitment to advancing medicinal chemistry. His achievements include awards from prominent conferences and academic institutions, underscoring his reputation in the scientific community. Dr. Abdelmonsef’s h-index of 17 is a testament to the impact of his research, and his contributions continue to influence the field of organic and medicinal chemistry. His recognition highlights his dedication to innovation in chemical research and his commitment to advancing drug discovery.

Publications đź“š

Dr. Abdelmonsef has an extensive list of publications, contributing to the fields of organic chemistry and drug design. His works include:

  • Synthesis, spectroscopic characterization, antimicrobial activity, and computational studies of five and/or six heterocyclic nitrogen rings linked to thienopyrazole moiety” – Journal of Molecular Structure (2024)
    This study explores the synthesis and structural analysis of heterocyclic compounds containing nitrogen rings connected to a thienopyrazole core. The research emphasizes antimicrobial activity assessment against various bacterial strains, with computational studies supporting the understanding of the binding interactions of these compounds with microbial proteins. The article has been widely cited for its methodology and results in medicinal chemistry research.
  • “Novel Pyrazole-Linked Pyran Hybrids: Synthesis, Anti-inflammatory Evaluation, Molecular Docking Studies” – Egyptian Journal of Chemistry (2024)
    This paper reports on the synthesis of pyrazole-pyran hybrid compounds, which were tested for anti-inflammatory properties. Molecular docking studies are also included, showing potential receptor interactions that may contribute to the anti-inflammatory effects observed. This research has been referenced broadly for its innovative approach to hybrid compound synthesis and its potential implications in anti-inflammatory drug development.
  • “New 1,3-Diphenyl-1H-pyrazol-5-ols as Anti-Methicillin Resistant Staphylococcus aureus Agents” – Heliyon (2024)
    Focused on combating Methicillin-resistant Staphylococcus aureus (MRSA), this study presents novel pyrazol-5-ols with potential antibacterial activity. The research is significant due to the pressing need for effective MRSA treatments, and the synthesized compounds exhibited promising activity. The paper contributes to the field by offering new compounds that could address antibiotic resistance.
  • “Synthesis, Characterization, Computer-aided Docking Studies, and Antifungal Activity of Two-armed Quinazolin-2,4-dione Derivatives” – Journal of Molecular Structure (2024)
    This work investigates quinazolin-2,4-dione derivatives for their antifungal properties. The study includes computational docking to predict interactions with fungal targets, assisting in understanding how these compounds might exert antifungal effects. The results have implications for the development of new antifungal agents.
  • “New Quinazolin-2,4-dione Derivatives Incorporating Acylthiourea, Pyrazole and/or Oxazole Moieties as Antibacterial Agents” – RSC Advances (2024)
    This study details the synthesis of quinazolin-2,4-dione derivatives modified with acylthiourea, pyrazole, or oxazole moieties. The derivatives were evaluated for antibacterial efficacy, and the findings suggest they are potent agents against various bacterial strains. This paper is valuable in antibacterial research, especially for its exploration of structural modifications to enhance bioactivity.

Conclusion

Dr. Abdelmonsef’s achievements in organic chemistry, bioinformatics, and drug design position him as a strong candidate for the Best Researcher Award. His publication history, citation impact, and international collaborations are significant strengths, while further diversification in research topics and methodologies could enhance his candidacy further. Overall, he demonstrates considerable expertise and dedication, making him a worthy nominee for this prestigious award.

 

Sihe Zhang | drug delivery | Best Scholar Award

Prof . Sihe Zhang | drug delivery | Best Scholar Award 

Director , Nankai University , China

Si-he Zhang is a tenured full professor at Nankai University’s School of Medicine, Department of Cell Biology. With extensive experience in cell biology, genetics, and oncology, his research focuses on cancer biology, antibody and vaccine research, and targeted cancer therapies. He has made significant contributions to the field through numerous publications, patents, and major research grants.

Profile

Scopus

Strengths for the Award

  1. Extensive Research Experience: Si-he Zhang has over two decades of research experience in cell biology, genetics, and cancer research. This depth of experience is evident in the numerous high-impact publications, many of which focus on cutting-edge therapeutic strategies for cancer.
  2. Notable Awards and Recognitions: Zhang has been recognized with prestigious awards, including the National Prize for Progress in Science & Technology in China and the Gold Award for Chinese Outstanding Patented Invention, which underscore his contributions to scientific advancement.
  3. Leadership and Influence: Zhang has held significant academic positions, such as a tenured full professorship at Nankai University, and has been involved in important scholarship committees. His role as a consultant to industry leaders further highlights his influence in both academic and industrial biotechnology sectors.
  4. Impressive Grant Record: Zhang has secured numerous major grants from national and regional funding bodies in China, which is a testament to his ability to lead and sustain high-impact research projects.
  5. Innovative Research Contributions: Zhang’s research has led to the development of novel therapeutic strategies and technologies, including hypoxia-activated antibodies for cancer treatment and suicide gene delivery methods for ovarian cancer therapy. These contributions are of significant value to the medical and scientific community.

Areas for Improvement

  1. Global Collaboration: While Zhang has extensive experience within China and some international experience (e.g., postdoctoral work in Sweden), expanding collaborations with a broader range of international research institutions could enhance the global impact of his work.
  2. Diversity of Research Topics: Zhang’s research is highly focused on cancer biology and cell biology. Expanding into related fields or interdisciplinary areas could further broaden the scope and application of his research, increasing its relevance to other fields of biomedical science.
  3. Teaching and Mentorship: Although Zhang has a strong teaching portfolio, highlighting specific outcomes or successes of his students and mentees could strengthen his case for an award focused on scholarly excellence, particularly if they have gone on to significant achievements under his guidance.

    Education

    • PhD in Cell Biology (2001-2004) from the Fourth Military Medical University, China.
    • M.A. in Genetics (1996-1998) from Jilin University, China.
    • B.S. in Genetics (1991-1995) from Northwest A&F University, China.

    Experience

    • Tenured Full Professor at Nankai University (2020-present).
    • Tenured Associate Professor at Nankai University (2012-2019).
    • Postdoctoral Scientist at Lund University Hospital, Sweden (2006-2009).
    • Associate Professor and Lecturer at Fourth Military Medical University (2000-2011).
    • Teaching Assistant at Fourth Military Medical University (1998-2000).

    Research Interests

    Si-he Zhang’s research encompasses cancer biology, cell engineering, and transgenic biology. He focuses on the development of novel therapeutic strategies for cancer treatment, including antibody-based therapies and targeted drug delivery systems.

    Awards

    • Gold Award for Chinese Outstanding Patented Invention (2010), WIPO-SIPO.
    • National Prize for Progress in Science & Technology (2005), China.

    Publications

    1. Hypoxia-activated ADCC-enhanced humanized anti-CD147 antibody for liver cancer imaging and targeted therapy (2024), MedComm, Cited by 5 articles.
    2. Hypoxia-activated selectivity-improved anti-PKM2 antibody for hepatocellular carcinoma (2024), International Journal of Biological Sciences, Cited by 3 articles.
    3. Suicide Gene Delivery by Morphology-Adaptable Enantiomeric Peptide Assemblies (2024), Acta Biomaterialia, Cited by 7 articles.
    4. Novel GIRlncRNA Signature for Predicting Clinical Outcome in NSCLC (2022), Frontiers in Pharmacology, Cited by 15 articles.
    5. GRP75-driven macropinocytosis of Tat/pDNA-Ca2+ nanoparticles in ovarian cancer (2022), Journal of Nanobiotechnology, Cited by 8 articles.

      Conclusion

      Si-he Zhang is a highly qualified candidate for the Best Scholar Award, with a robust record of research, significant contributions to cancer therapy, and notable academic leadership. His extensive publication history, major awards, and successful acquisition of research funding demonstrate his impact in the field of cell biology and cancer research. However, to further strengthen his candidacy, he could consider increasing his global collaborations and diversifying his research interests. Overall, Zhang’s accomplishments make him a strong contender for the award, reflecting his dedication to advancing scientific knowledge and medical innovation.